Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers.
|
19202148 |
2009 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers.
|
20238042 |
2010 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD has a strong genetic association with high-temperature requirement A 1 (HTRA1).
|
30273602 |
2018 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HTRA1 gene polymorphism may influence patient response to treatment with intravitreal ranibizumab for neovascular AMD.
|
24080590 |
2013 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26.
|
19933195 |
2010 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis.
|
28637435 |
2017 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Binary logistic regression analysis binary logistic regression analysis revealed an odds ratio (OR) of 2.7 (95% confidence interval (CI): 1.1-6.8) for AMD among subjects heterozygous for the HTRA1 -625A allele compared to those with the wildtype genotype, when adjusted for CFH Y402H genotypes (p=0.034).
|
17679948 |
2007 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CFH (rs1410996), HTRA1 (rs112000638) and ARMS2 (rs10490923) gene polymorphisms are associated with AMD risk in Spanish patients.
|
23534868 |
2014 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CFH, ARMS2 and HTRA1 genotypes may influence patient response to treatment with intravitreal bevacizumab for neovascular AMD.
|
22594510 |
2012 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we confirm that ARMS2, HTRA1 and CFH variants are associated with neovascular AMD in the Thai population.
|
28703135 |
2017 |
Glycogen storage disease type II
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only one locus, the ARMS2/HTRA1 was a significant genetic risk factor for Korean exudative AMD, including its subtypes, PCV and typical CNV.
|
26171855 |
2015 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Other than variants on 1q32-q22, only two SNPs, rs9288410 (MAP2) on 2q34-q35 and rs2014307 (PLEKHA1/HTRA1) on 10q26 were significantly associated with AMD status (P = .03 and P < 10-6 respectively).
|
18541031 |
2008 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results revealed that HTRA1 rs2672598 is more significantly associated with exudative AMD than PCV in ARMS2/HTRA1 region, and it is responsible for elevated HTRA1 transcriptional activity and HTRA1 protein expression.
|
27338780 |
2016 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Significantly, interactions were identified among FPR1 rs78488639, CFH rs800292, and HTRA1 rs11200638 in both exudative AMD and PCV.
|
25277308 |
2014 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Six single nucleotide polymorphisms (SNPs) in this region and two known AMD-associated SNPs in CFH (rs800292) and HTRA1 (rs11200638) were genotyped in a Han Chinese cohort composed of 490 neovascular AMD patients, 419 PCV patients and 1316 controls.
|
26861912 |
2016 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Synonymous variants in HTRA1 implicated in AMD susceptibility impair its capacity to regulate TGF-β signaling.
|
26310622 |
2015 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HTRA1 promoter polymorphism, rs11200638, is a strong candidate with a functional consequence that predisposes Japanese to develop neovascular AMD.
|
17438519 |
2007 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association of SKIV2L rs429608 with neovascular AMD remained significant after adjusting for CFH rs800292 and HTRA1 rs11200638.
|
23260260 |
2013 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The coding HTRA1 SNP rs2293870, not part of the significant haplotypes containing rs10490924 and rs11200638, showed as strong an association with increased susceptibility to neovascular AMD.
|
18164066 |
2008 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The LOC387715/HTRA1 variants are associated with PCV and wet AMD in the Japanese population.
|
17692272 |
2007 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ORs of exudative AMD for individuals carrying one copy risk allele and two copy risk alleles were 2.57 (1.21 - 5.45) and 4.76 (2.15 - 10.55) respectively, with correspondent PARs of 28.3% (2.0% - 40.5%) and 38.2% (21.8% - 45.4%). rs11200638 in HTRA1 was another susceptible locus for AMD and the risk homozygotes were significantly susceptible for exudutive AMD (OR = 3.98, 1.88 - 8.43) with PAR of 38.9% (24.3% - 45.8%).
|
19187590 |
2008 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is a strong and consistent association of the ARMS2/HTRA1 locus with both exudative AMD and PCV, suggesting the two disorders share, at least partially, similar molecular mechanisms.
|
22491416 |
2012 |
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no significant difference in the incidence of CFH Y402H (P = 0.598) and HTRA1 rs11200638 (P = 0.290) between eyes with typical exudative AMD and with PCV.
|
18939352 |
2008 |
Glycogen storage disease type II
|
0.100 |
Biomarker
|
disease |
BEFREE |
This finding is consistent with the role of HTRA1 in AMD pathogenesis and will help aid in the clinical management and prognosis of AMD patients.
|
18206206 |
2008 |
Glycogen storage disease type II
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrated the significant association of the 10q26 SNPs (HTRA1 and LOC387715) in an AMD cohort from Korea and was consistent with previous studies from other populations.
|
20456446 |
2010 |